NASDAQ:PSNL Personalis (PSNL) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free PSNL Stock Alerts $1.63 +0.02 (+1.24%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.59▼$1.6650-Day Range$1.15▼$2.1952-Week Range$0.89▼$3.27Volume229,442 shsAverage Volume436,931 shsMarket Capitalization$82.32 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Personalis alerts: Email Address Personalis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside237.4% Upside$5.50 Price TargetShort InterestHealthy2.25% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$1,702 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.58) to ($1.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.55 out of 5 starsMedical Sector86th out of 947 stocksMedical Laboratories Industry4th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Personalis has a forecasted upside of 237.4% from its current price of $1.63.Amount of Analyst CoveragePersonalis has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.25% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Personalis has recently decreased by 2.57%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePersonalis has received a 60.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools" and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Personalis is -0.66. Previous Next 2.7 News and Social Media Coverage News SentimentPersonalis has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Personalis this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for PSNL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Personalis to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,702.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of Personalis is held by insiders.Percentage Held by Institutions53.76% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($1.58) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Personalis Stock (NASDAQ:PSNL)Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.Read More PSNL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSNL Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comPSNL Apr 2024 2.500 putMarch 6, 2024 | finance.yahoo.comPSNL Apr 2024 7.500 callMarch 18, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. March 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Personalis’s Strategic Advances and Financial Health Signal Promising Growth in 2024March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Personalis Amidst Strategic Partnerships and Revenue Growth ProspectsMarch 1, 2024 | seekingalpha.comPersonalis, Inc. (PSNL) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | uk.finance.yahoo.comPersonalis, Inc. (PSNL)February 29, 2024 | finance.yahoo.comPersonalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call TranscriptMarch 18, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 28, 2024 | benzinga.comPersonalis: Q4 Earnings InsightsFebruary 28, 2024 | finance.yahoo.comPersonalis Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | markets.businessinsider.comWhat Wall Street expects from Personalis's earningsFebruary 14, 2024 | finance.yahoo.comPersonalis to Announce Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | businesswire.comPersonalis to Announce Fourth Quarter and Full Year 2023 Financial ResultsJanuary 31, 2024 | finance.yahoo.comPersonalis to Participate at Upcoming Investor ConferencesJanuary 30, 2024 | markets.businessinsider.comPersonalis, ClearNote Health Join Hands To Advance Epigenomic TechnologyJanuary 30, 2024 | finance.yahoo.comPersonalis and ClearNote Health Announce Partnership to Advance Epigenomic TechnologyJanuary 22, 2024 | finance.yahoo.comPersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 16, 2024 | finance.yahoo.comPersonalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling AssayJanuary 7, 2024 | uk.investing.comPersonalis reports 18% Q4 revenue growth, eyes 2026 runwayJanuary 6, 2024 | markets.businessinsider.comBuy Rating for Personalis Amid Strong Growth and Promising VA MVP DevelopmentsJanuary 5, 2024 | markets.businessinsider.comPersonalis Expects Q4 Revenue To Grow 18%January 3, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Personalis (PSNL)December 18, 2023 | finance.yahoo.comEven With A 37% Surge, Cautious Investors Are Not Rewarding Personalis, Inc.'s (NASDAQ:PSNL) Performance CompletelyDecember 4, 2023 | finance.yahoo.comPersonalis Extends Cash Position Into 2026, Provides Update on Key InitiativesDecember 1, 2023 | bizjournals.comEast Bay cancer test company to shed another 65 jobsDecember 1, 2023 | msn.comCancer test developer Personalis to cut 65 jobs to reduce costsSee More Headlines Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/18/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:PSNL CUSIPN/A CIK1527753 Webwww.personalis.com Phone(650) 752-1300FaxN/AEmployees395Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$7.50 Low Stock Price Target$3.50 Potential Upside/Downside+243.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,300,000.00 Net Margins-147.38% Pretax Margin-147.27% Return on Equity-61.42% Return on Assets-41.05% Debt Debt-to-Equity RatioN/A Current Ratio3.11 Quick Ratio2.88 Sales & Book Value Annual Sales$73.48 million Price / Sales1.10 Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book0.61Miscellaneous Outstanding Shares50,500,000Free Float46,716,000Market Cap$80.80 million OptionableOptionable Beta1.96 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Christopher M. Hall (Age 55)President, CEO & Director Comp: $506.39kMr. Aaron L. Tachibana (Age 63)CFO & COO Comp: $569.6kDr. Richard Chen M.D. (Age 53)M.S., Executive VP of R&D and Chief Medical Officer Comp: $584.17kDr. Russ B. Altman M.D.Ph.D., Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Euan A. Ashley DPHIL (Age 52)FRCP, M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board Dr. Michael P. Snyder Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardMr. Stephen M. Moore J.D. (Age 51)VP, General Counsel & Corporate Secretary Mr. Michael J FitzpatrickVice President of Worldwide SalesDr. Christian Haudenschild Ph.D.Senior Vice President of Genomic Laboratory OperationsMr. Stephane Mouradian Ph.D.Senior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsEnzo BiochemNYSE:ENZGenetronNASDAQ:GTHAkuminNASDAQ:AKUMQExagenNASDAQ:XGNBiodesixNASDAQ:BDSXView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Bought 49,233 shares on 3/1/2024Ownership: 0.192%GSA Capital Partners LLPBought 258,285 shares on 2/16/2024Ownership: 0.807%Bridgeway Capital Management LLCSold 25,000 shares on 2/15/2024Ownership: 0.264%Royal Bank of CanadaBought 18,300 shares on 2/14/2024Ownership: 0.192%Pathstone Holdings LLCBought 36,396 shares on 2/14/2024Ownership: 0.074%View All Insider TransactionsView All Institutional Transactions PSNL Stock Analysis - Frequently Asked Questions Should I buy or sell Personalis stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PSNL shares. View PSNL analyst ratings or view top-rated stocks. What is Personalis' stock price target for 2024? 2 brokerages have issued 12-month price targets for Personalis' shares. Their PSNL share price targets range from $3.50 to $7.50. On average, they anticipate the company's share price to reach $5.50 in the next year. This suggests a possible upside of 237.4% from the stock's current price. View analysts price targets for PSNL or view top-rated stocks among Wall Street analysts. How have PSNL shares performed in 2024? Personalis' stock was trading at $2.10 at the start of the year. Since then, PSNL stock has decreased by 22.4% and is now trading at $1.63. View the best growth stocks for 2024 here. When is Personalis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our PSNL earnings forecast. How were Personalis' earnings last quarter? Personalis, Inc. (NASDAQ:PSNL) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.40) earnings per share for the quarter, hitting the consensus estimate of ($0.40). The business had revenue of $22.26 million for the quarter, compared to the consensus estimate of $22.20 million. Personalis had a negative net margin of 147.38% and a negative trailing twelve-month return on equity of 61.42%. During the same quarter last year, the company earned ($0.27) EPS. What ETF holds Personalis' stock? ARK Genomic Revolution ETF holds 5,920,884 shares of PSNL stock, representing 0.56% of its portfolio. What guidance has Personalis issued on next quarter's earnings? Personalis issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18.0 million-$19.0 million, compared to the consensus revenue estimate of $19.1 million. What is John West's approval rating as Personalis' CEO? 17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and When did Personalis IPO? (PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager. Who are Personalis' major shareholders? Personalis' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (13.61%), GSA Capital Partners LLP (0.81%), Bruce & Co. Inc. (0.61%), Bridgeway Capital Management LLC (0.26%), Green Alpha Advisors LLC (0.24%) and Dimensional Fund Advisors LP (0.22%). Insiders that own company stock include Aaron Tachibana, Christopher M Hall, John Stephen West, Lightspeed Venture Partners Se, Richard Chen and Stephen Michael Moore. View institutional ownership trends. How do I buy shares of Personalis? Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PSNL) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.